Established TAAs were selected for each of the five cancer types commonly seen in allogeneic vaccine clinical trials: Gp100, Ny-ESO-1, and MART-1 for melanoma (SKCM); VEGFR1 and Ny-ESO-1 for lung adenocarcinoma (LUAD); VEGFR1 and Ny-ESO-1 for lung squamous carcinoma (LUSC); PSA and PAP for prostate adenocarcinoma (PRAD); and MUC1 and Mesothelin for pancreatic adenocarcinoma (PAAD). The gene discussed is FLT1; the disease is prostate adenocarcinoma.